FILE PHOTO: Tennis player Simona Halep of Romania speaks to the media, on the hearing day of a doping case against her at the Court of Arbitration for Sport (CAS) in Lausanne, Switzerland February 9, 2024. REUTERS/Denis Balibouse/File Photo
BENGALURU (Reuters) - Simona Halep questioned the "big difference" in how doping cases are treated after world number two Iga Swiatek was handed a one-month drugs ban while the Romanian was out of action for over 18 months following two separate anti-doping violations.
The International Tennis Integrity Agency (ITIA) said on Thursday that Swiatek had accepted a one-month suspension after testing positive for the banned substance trimetazidine (TMZ).
The Pole tested positive in August but the ITIA, which runs tennis's anti-doping programme, accepted that it was caused by contamination of her medication melatonin.
Halep was provisionally suspended in October 2022 and later banned for four years, a period which was reduced to nine months in March after an appeal at the Court of Arbitration for Sport.
She had strongly denied knowingly taking the banned substance roxadustat and said she had evidence to show small amounts of the anaemia drug entered her system from a contaminated licensed supplement.
"I stand and ask myself, why is there such a big difference in treatment and judgment?" former world number one Halep said in a post on Instagram on Thursday. "I can't find and I don't think there can be a logical answer.
"It can only be bad will from the ITIA, the organisation that has done absolutely everything to destroy me despite the evidence ... It was painful, it is painful and maybe the injustice that was done to me will always be painful."
Reuters has contacted the ITIA for comment.
Former Wimbledon and French Open champion Halep had criticised tennis authorities for the length of time it took to process her case. After her provisional suspension in October 2022, Halep received her four-year ban in September 2023.
Swiatek, who was world number one when she failed the test, was provisionally suspended on Sept. 12, but had it lifted on Oct. 4, leaving her with just over a week's ban to serve.
Players on both tours called out what they perceived as double standards in the sport when men's world number one Jannik Sinner was cleared of wrongdoing despite failing two drug tests earlier this year.
An independent tribunal accepted the Italian's explanation that the anabolic agent clostebol had entered his system from a member of his support team through massages and sports therapy.
Sinner could still be banned for up to two years with the World Anti-Doping Agency appealing the decision in his case at sport's highest court.
Amid questions about the handling of the cases of Swiatek and Sinner, ITIA chief executive Karen Moorhouse said at a media briefing on Thursday: "These aren't cases of intentional doping. We're dealing with inadvertent breaches of the rules.
"So I don't think this is a cause for concern for tennis fans. The fact that we're being clearly open, transparent, and it shows the breadth and depth of our anti-doping programme."
The Professional Tennis Players Association (PTPA), which was established by Novak Djokovic and Vasek Pospisil in 2020, said late on Thursday that tennis needed an anti-doping system rooted in transparency, consistency and objectivity.
"Players deserve and are entitled to due process and support in navigating the anti-doping system, regardless of ranking and access to resources ... (They) deserve and are entitled to governance that they trust," the advocacy group added.
"Our fight to overhaul the failing tennis system continues."
(Reporting by Shrivathsa Sridhar in Bengaluru; Editing by Peter Rutherford)
